Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025BOSTON, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that positive interim data from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial was presented at the American Heart Association (AHA) Scientific Sessions 2025 taking place November 7-10, 2025, in New Orleans, Louisiana.
Medera Announces First Patient Dosed in Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial Evaluating SRD-001 Gene Therapy for Heart Failure with Reduced Ejection FractionBOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the first patient has been dosed in the Phase 2 portion of the MUSIC-HFrEF Phase 1b/2 clinical trial evaluating the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HFrEF). The patient was successfully treated on September 5, 2025, and additional patients are scheduled for treatment.
Medera Strengthens Leadership Team with Three Key Executive AppointmentsClinical operations, regulatory affairs, technical expertise, and corporate leadership additions support advancing gene therapy pipeline for cardiovascular diseases
